MCID: GLM045
MIFTS: 61

Glioma

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Glioma

MalaCards integrated aliases for Glioma:

Name: Glioma 49 36 28 51 69

Classifications:



External Ids:

KEGG 36 H00042

Summaries for Glioma

NIH Rare Diseases : 49 Glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. It is generally classified based on which type of glial cell is involved in the tumor: Astocytoma - tumors that develop from star-shaped glial cells called astrocytes Ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord Oligodendrogliomas - tumors that affect the oligodendrocytes The symptoms of glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. The exact underlying cause is unknown. In most cases, the tumor occurs sporadically in people with no family history of the condition. Treatment depends on many factors, including the type, size, stage and location of the tumor, but may include surgery, radiation therapy, chemotherapy and/or targeted therapy. Last updated: 7/15/2015

MalaCards based summary : Glioma is related to brain stem glioma and glioma susceptibility 1. An important gene associated with Glioma is LGI1 (Leucine Rich Glioma Inactivated 1), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 475)
# Related Disease Score Top Affiliating Genes
1 brain stem glioma 34.3 EGFR H3F3A TP53
2 glioma susceptibility 1 34.1 ERBB2 H3F3A HIST1H3A IDH1 IDH2 TP53
3 malignant glioma 33.8 DMBT1 EGFR MDM2 MMP2 PTEN TP53
4 gliosarcoma 32.4 EGFR IDH1 MMP2 PTEN TP53
5 astrocytoma 32.2 CCND1 DMBT1 EGFR IDH1 MDM2 MMP2
6 retinoblastoma 32.1 CCND1 CDK6 MDM2 TP53
7 oligodendroglioma 30.9 EGFR IDH1 IDH2 PTEN TP53
8 brain cancer 30.5 DMBT1 EGFR IDH1 IDH2 PTEN TP53
9 gliomatosis cerebri 30.4 EGFR IDH1 MDM2 PTEN TP53
10 anaplastic oligodendroglioma 30.2 EGFR IDH1 IDH2
11 spinal cord astrocytoma 30.1 H3F3A IDH1 TP53
12 cerebellar astrocytoma 30.1 IDH1 TP53
13 adenocarcinoma 30.1 CCND1 EGFR ERBB2 MMP2 TP53
14 melanoma 30.1 AKT3 CCND1 CDK6 MAGED4B PTEN TP53
15 malignant peripheral nerve sheath tumor 29.8 EGFR MDM2 TP53
16 diffuse large b-cell lymphoma 29.8 CCND1 MDM2 TP53
17 squamous cell carcinoma 29.8 CCND1 EGFR ERBB2 MMP2 PTEN TP53
18 nasopharyngeal carcinoma 29.7 CCND1 EGFR MDM2 MMP2 TP53
19 leukemia, acute myeloid 29.7 IDH1 IDH2 MDM2 TP53
20 osteogenic sarcoma 29.7 BAX MDM2 MMP2 TP53
21 glioblastoma 29.7 AKT3 CCND1 CDK6 DMBT1 EGFR ERBB2
22 gastric cancer 29.4 BAX CCND1 EGFR ERBB2 MMP2 PTEN
23 hepatocellular carcinoma 29.3 BAX CCND1 CDK6 EGFR MDM2 MMP2
24 glioblastoma multiforme 29.1 AKT3 CCND1 CDK6 DMBT1 EGFR ERBB2
25 pancreatic cancer 28.9 BAX CCND1 CDK6 EGFR ERBB2 MMP2
26 ovarian cancer 28.8 AKT3 BAX CCND1 EGFR ERBB2 MDM2
27 lung cancer 28.7 BAX CCND1 CDK6 DMBT1 EGFR ERBB2
28 prostate cancer 28.6 AKT3 BAX CCND1 EGFR ERBB2 GLIPR1
29 breast cancer 28.4 BAX CCND1 CDK6 EGFR ERBB2 MDM2
30 optic nerve glioma 12.3
31 diffuse intrinsic pontine glioma 12.3
32 childhood brain stem glioma 12.2
33 optic pathway glioma 12.2
34 glioma susceptibility 2 12.1
35 glioma susceptibility 3 12.1
36 glioma susceptibility 9 12.1
37 brain glioma 12.1
38 mixed glioma 12.0
39 chordoid glioma 12.0
40 third ventricle chordoid glioma 12.0
41 subependymal glioma 12.0
42 spinal cord glioma 12.0
43 childhood optic nerve glioma 12.0
44 angiocentric glioma 12.0
45 glioma susceptibility 4 11.8
46 glioma susceptibility 6 11.8
47 glioma susceptibility 8 11.8
48 adult brainstem mixed glioma 11.8
49 glioma susceptibility 5 11.8
50 glioma susceptibility 7 11.8

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma

Symptoms & Phenotypes for Glioma

GenomeRNAi Phenotypes related to Glioma according to GeneCards Suite gene sharing:

25 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.13 HIST1H3A
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.13 CDK6
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.13 CDK6 ERBB2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.13 HIST1H3A
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.13 HIST1H3A
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.13 CDK6
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.13 HIST1H3A
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.13 HIST1H3A
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.13 HIST1H3A MAGED4B CDK6 ERBB2 AKT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.13 CDK6
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.13 ERBB2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.13 CDK6 AKT3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 10.13 MAGED4B
14 Decreased viability GR00055-A-2 9.98 EGFR
15 Decreased viability GR00107-A-1 9.98 PRKCA
16 Decreased viability GR00221-A-1 9.98 PRKCA CDK6 EGFR AKT3
17 Decreased viability GR00221-A-2 9.98 AKT3 PRKCA CDK6
18 Decreased viability GR00221-A-3 9.98 AKT3 ERBB2
19 Decreased viability GR00221-A-4 9.98 PRKCA CDK6 EGFR ERBB2 AKT3
20 Decreased viability GR00301-A 9.98 AKT3 CDK6
21 Decreased viability GR00342-S-1 9.98 PRKCA
22 Decreased viability GR00342-S-2 9.98 PRKCA
23 Decreased viability GR00342-S-3 9.98 PRKCA
24 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 AKT3 PRKCA PTEN EGFR ERBB2
25 Increased cell viability after pRB stimulation GR00230-A-1 8.92 PRKCA EGFR ERBB2 AKT3

MGI Mouse Phenotypes related to Glioma:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 PTEN BAX DMBT1 EGFR TP53 CCND1
2 growth/size/body region MP:0005378 10.29 CDK6 PTEN BAX EGFR TP53 CCND1
3 mortality/aging MP:0010768 10.28 CDK6 PTEN BAX DMBT1 EGFR TP53
4 cardiovascular system MP:0005385 10.26 CDK6 PTEN EGFR TP53 CCND1 AKT3
5 neoplasm MP:0002006 10.21 PTEN BAX DMBT1 EGFR TP53 CCND1
6 immune system MP:0005387 10.2 AKT3 CDK6 DMBT1 PTEN BAX EGFR
7 endocrine/exocrine gland MP:0005379 10.19 AKT3 CDK6 PTEN BAX EGFR TP53
8 nervous system MP:0003631 10.1 PRKCA AKT3 PTEN BAX EGFR TP53
9 muscle MP:0005369 10.06 CDK6 PTEN BAX EGFR TP53 MMP2
10 reproductive system MP:0005389 9.85 AKT3 CDK6 PTEN BAX EGFR TP53
11 pigmentation MP:0001186 9.65 PTEN TP53 MDM2 LGI1 EGFR
12 respiratory system MP:0005388 9.56 PTEN BAX EGFR TP53 CCND1 ERBB2
13 skeleton MP:0005390 9.28 PTEN BAX EGFR TP53 CCND1 MDM2

Drugs & Therapeutics for Glioma

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 658)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
8
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
9 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
10
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
11
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
12
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
13 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
14
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
16
Trametinib Approved Phase 4,Phase 2,Phase 1 871700-17-3 11707110
17
Dabrafenib Approved, Investigational Phase 4,Phase 2,Phase 1 44462760 44516822
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
20 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1
21
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
22 Etiracetam Investigational Phase 4,Phase 1,Phase 2 33996-58-6
23
Lactitol Investigational Phase 4,Phase 2,Phase 1 585-86-4 3871
24 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
26 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
33 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
36 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
43 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Neuroprotective Agents Phase 4,Phase 2,Phase 1
47 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
49 Anti-Anxiety Agents Phase 4,Phase 2
50 Antimanic Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 2005)

# Name Status NCT ID Phase Drugs
1 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
2 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
4 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
5 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
7 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
8 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
9 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
10 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
11 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
12 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
13 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
14 Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Unknown status NCT01878266 Phase 3
15 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
16 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
17 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
18 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
19 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
20 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
21 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
22 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
23 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
24 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
25 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
26 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
27 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
28 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
29 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
30 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
31 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
32 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
33 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
34 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
35 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
36 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
37 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
38 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
39 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
40 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
41 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
42 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
43 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
44 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
45 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
46 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
47 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
48 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
49 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
50 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo

Search NIH Clinical Center for Glioma

Genetic Tests for Glioma

Genetic tests related to Glioma:

# Genetic test Affiliating Genes
1 Glioma 28

Anatomical Context for Glioma

MalaCards organs/tissues related to Glioma:

38
Brain, T Cells, Endothelial, Spinal Cord, Bone, Testes, Bone Marrow

Publications for Glioma

Articles related to Glioma:

(show top 50) (show all 6807)
# Title Authors Year
1
Snail regulates BMP and TGFI^ pathways to control the differentiation status of glioma-initiating cells. ( 29449696 )
2018
2
Highly Efficient Glioma Targeting of Tat Peptide-TTA1 Aptamer-Polyephylene Glycol-Modified Gelatin-Siloxane Nanoparticles. ( 29442899 )
2018
3
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. ( 29432077 )
2018
4
Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. ( 29392423 )
2018
5
A Spatio-temporal Model of Macrophage-mediated Drug Resistance in Glioma Immunotherapy. ( 29440290 )
2018
6
Tumefactive Multiple Sclerosis Masquerading as High Grade Glioma. ( 29331745 )
2018
7
ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. ( 29017962 )
2018
8
Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma. ( 29343959 )
2018
9
REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. ( 29435175 )
2018
10
B<i>m</i>K CT enhances the sensitivity of temozolomide-induced apoptosis of malignant glioma U251 cells<i>in vitro</i>through blocking the AKT signaling pathway. ( 29434848 )
2018
11
Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells. ( 29434995 )
2018
12
I^-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells. ( 28776671 )
2018
13
Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. ( 28903484 )
2018
14
GBP3 promotes glioma cell proliferation via SQSTM1/p62-ERK1/2 axis. ( 29128363 )
2018
15
Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. ( 29444818 )
2018
16
Prognostic significance of epidermal growth factor receptor expression in glioma patients. ( 29445288 )
2018
17
Comparative dynamics of microglial and glioma cell motility at the infiltrative margin of brain tumours. ( 29445035 )
2018
18
Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. ( 29251333 )
2018
19
Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro. ( 29364085 )
2018
20
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells. ( 29208287 )
2018
21
Expression and functional analysis of TCF4 isoforms in human glioma cells. ( 29436621 )
2018
22
Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. ( 29343527 )
2018
23
T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. ( 29151166 )
2018
24
MicroRNA-375 inhibits glioma cell proliferation and migration by downregulating RWDD3 inA vitro. ( 29436665 )
2018
25
NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. ( 29440289 )
2018
26
Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2. ( 29436609 )
2018
27
Value of<sup>18</sup>F-FET PET in adult brainstem glioma. ( 29448122 )
2018
28
Down-regulation of miRNA-320c promotes tumor growth and metastasis and predicts poor prognosis in human glioma. ( 29438779 )
2018
29
The trans-laminar terminalis approach reduces mortalities associated with chordoid glioma resections: A case report and a review of 20a8^years of literature. ( 29066234 )
2018
30
End-of-life care of children with diffuse intrinsic pontine glioma. ( 29397521 )
2018
31
CYP4X1 inhibition by flavonoid CH625 normalizes glioma vasculature through reprogramming TAMs<i>via</i>CB2 and EGFR-STAT3 axis. ( 29437915 )
2018
32
Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. ( 29391393 )
2018
33
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. ( 29305708 )
2018
34
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. ( 29133513 )
2018
35
Immunotherapies for malignant glioma. ( 29242608 )
2018
36
Expression of CXC-motif-chemokine 12 and the receptor C-X-C receptor 4 in glioma and theeffect on peritumoral brain edema. ( 29434965 )
2018
37
Optic Nerve Glioma in Two Sisters with Family History of Neurofibromatosis Type 1. ( 29294511 )
2018
38
Allicin induces apoptosis through activation of both intrinsic and extrinsic pathways in glioma cells. ( 29436625 )
2018
39
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. ( 29143272 )
2018
40
Methylation-induced downregulation and tumor-suppressive role of microRNA-98 in glioma through targeting Sal-like protein 4. ( 29436585 )
2018
41
Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. ( 29143923 )
2018
42
Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. ( 29441040 )
2018
43
Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis. ( 29310118 )
2018
44
"Simple Methods to Derive Primary Malignant Glioma Cell Lines and Assay of Cellular Damage for Preclinical Studies". ( 29405781 )
2018
45
Editorial: The Role of Microenvironment in the Homing, Maintenance, and Release of Glioma Stem-Like Cells. ( 29441325 )
2018
46
A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker. ( 29444091 )
2018
47
Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. ( 29207163 )
2018
48
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. ( 29404979 )
2018
49
Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. ( 29049847 )
2018
50
MAGEA6 promotes human glioma cell survival via targeting AMPKI+1. ( 29024810 )
2018

Variations for Glioma

Cosmic variations for Glioma:

9 (show top 50) (show all 92)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43714 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.836G>A p.G279E 4
2 COSM11166 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.406C>T p.Q136* 4
3 COSM10810 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.725G>T p.C242F 4
4 COSM44310 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.738G>A p.M246I 4
5 COSM10659 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.817C>T p.R273C 4
6 COSM44249 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.623A>T p.D208V 4
7 COSM44224 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.721T>G p.S241A 4
8 COSM44219 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.405C>G p.C135W 4
9 COSM10656 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.742C>T p.R248W 4
10 COSM43903 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.470T>G p.V157G 4
11 COSM10911 TP53 central nervous system,brain,glioma,ependymoma Grade III-IV c.847C>T p.R283C 4
12 COSM44964 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.719G>C p.S240T 4
13 COSM10648 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.524G>A p.R175H 4
14 COSM45672 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.376-2A>G p.? 4
15 COSM44327 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.518T>C p.V173A 4
16 COSM10726 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.856G>A p.E286K 4
17 COSM43708 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.422G>A p.C141Y 4
18 COSM43755 TP53 central nervous system,brain,glioma,oligodendroglioma Grade II c.833C>A p.P278H 4
19 COSM5974 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.209+1G>C p.? 4
20 COSM5128 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.977A>G p.D326G 4
21 COSM5109 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.302T>C p.I101T 4
22 COSM5097 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.131G>A p.G44D 4
23 COSM5127 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.170T>C p.L57S 4
24 COSM5149 PTEN central nervous system,brain,glioma,ependymoma Grade III-IV c.511C>T p.Q171* 4
25 COSM5114 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.494G>A p.G165E 4
26 COSM5193 PTEN central nervous system,brain,glioma,oligodendroglioma Grade II c.384G>T p.K128N 4
27 COSM763 PIK3CA central nervous system,brain,glioma,oligodendroglioma Grade II c.1633G>A p.E545K 4
28 COSM767 PIK3CA central nervous system,brain,glioma,oligodendroglioma Grade II c.1637A>C p.Q546P 4
29 COSM775 PIK3CA central nervous system,brain,glioma,oligodendroglioma Grade II c.3140A>G p.H1047R 4
30 COSM12459 PIK3CA central nervous system,brain,glioma,oligodendroglioma Grade II c.1637A>G p.Q546R 4
31 COSM760 PIK3CA central nervous system,brain,glioma,oligodendroglioma Grade II c.1624G>A p.E542K 4
32 COSM746 PIK3CA central nervous system,brain,glioma,oligodendroglioma Grade II c.263G>A p.R88Q 4
33 COSM24850 NRAS central nervous system,brain,glioma,oligodendroglioma Grade II c.29G>A p.G10E 4
34 COSM23869 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.675+1G>A p.? 4
35 COSM23667 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.1396C>T p.R466* 4
36 COSM24624 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.675+5G>A p.? 4
37 COSM22432 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.592C>T p.R198* 4
38 COSM4169562 MSH6 central nervous system,brain,glioma,oligodendroglioma Grade II c.2581G>T p.A861S 4
39 COSM4169560 MSH6 central nervous system,brain,glioma,oligodendroglioma Grade II c.1801C>G p.L601V 4
40 COSM692 MET central nervous system,brain,glioma,oligodendroglioma Grade II c.3410G>T p.G1137V 4
41 COSM23159 MEN1 central nervous system,spinal cord,glioma,ependymoma Grade II c.1413G>A p.W471* 4
42 COSM518 KRAS central nervous system,brain,glioma,oligodendroglioma Grade II c.34G>C p.G12R 4
43 COSM33732 IDH2 central nervous system,brain,glioma,oligodendroglioma Grade II c.515G>T p.R172M 4
44 COSM33733 IDH2 central nervous system,brain,glioma,oligodendroglioma Grade II c.515G>A p.R172K 4
45 COSM34039 IDH2 central nervous system,brain,glioma,oligodendroglioma Grade II c.514A>T p.R172W 4
46 COSM28746 IDH1 central nervous system,brain,glioma,oligodendroglioma Grade II c.395G>A p.R132H 4
47 COSM28749 IDH1 central nervous system,brain,glioma,oligodendroglioma Grade II c.394C>G p.R132G 4
48 COSM28747 IDH1 central nervous system,brain,glioma,oligodendroglioma Grade II c.394C>T p.R132C 4
49 COSM88208 IDH1 central nervous system,brain,glioma,oligodendroglioma Grade II c.299G>A p.R100Q 4
50 COSM28748 IDH1 central nervous system,brain,glioma,oligodendroglioma Grade II c.394C>A p.R132S 4

Copy number variations for Glioma from CNVD:

7 (show top 50) (show all 1065)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion BC037540 Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma

Expression for Glioma

Search GEO for disease gene expression data for Glioma.

Pathways for Glioma

Pathways related to Glioma according to KEGG:

36
# Name Kegg Source Accession
1 Glioma hsa05214
2 MicroRNAs in cancer hsa05206

Pathways related to Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 AKT3 CCND1 EGFR ERBB2 GLIPR1 HIST1H3A
2
Show member pathways
13.95 AKT3 BAX EGFR ERBB2 H3F3A HIST1H3A
3
Show member pathways
13.91 AKT3 BAX CCND1 CDK6 EGFR ERBB2
4
Show member pathways
13.89 AKT3 BAX EGFR ERBB2 H3F3A HIST1H3A
5
Show member pathways
13.61 AKT3 BAX EGFR ERBB2 H3F3A HIST1H3A
6
Show member pathways
13.57 AKT3 EGFR ERBB2 H3F3A HIST1H3A LGI1
7
Show member pathways
13.5 AKT3 CCND1 CDK6 H3F3A HIST1H3A MDM2
8
Show member pathways
13.5 AKT3 BAX CCND1 EGFR ERBB2 MDM2
9
Show member pathways
13.31 AKT3 BAX CCND1 EGFR ERBB2 PRKCA
10
Show member pathways
13.17 AKT3 EGFR ERBB2 MDM2 PTEN TP53
11
Show member pathways
13.12 AKT3 EGFR MDM2 PRKCA PTEN TP53
12
Show member pathways
13.12 AKT3 BAX CCND1 CDK6 EGFR ERBB2
13
Show member pathways
13.06 AKT3 BAX CCND1 CDK6 EGFR MDM2
14
Show member pathways
13 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
15
Show member pathways
12.85 AKT3 CCND1 CDK6 PRKCA TP53
16
Show member pathways
12.83 AKT3 EGFR ERBB2 MDM2 PTEN TP53
17
Show member pathways
12.82 AKT3 BAX ERBB2 PRKCA PTEN TP53
18
Show member pathways
12.81 AKT3 BAX CCND1 CDK6 EGFR ERBB2
19
Show member pathways
12.77 AKT3 CCND1 EGFR MMP2 PRKCA PTEN
20
Show member pathways
12.7 AKT3 BAX EGFR ERBB2 MMP2 TP53
21
Show member pathways
12.69 AKT3 BAX CCND1 CDK6 PRKCA PTEN
22
Show member pathways
12.65 AKT3 CCND1 CDK6 MDM2 TP53
23
Show member pathways
12.61 AKT3 EGFR ERBB2 PRKCA PTEN TP53
24
Show member pathways
12.61 AKT3 EGFR ERBB2 MDM2 PRKCA TP53
25 12.6 CCND1 CDK6 HIST1H3A MDM2 TP53
26
Show member pathways
12.59 AKT3 CCND1 EGFR ERBB2 MDM2 PRKCA
27 12.59 CCND1 CDK6 EGFR ERBB2 MDM2 PRKCA
28
Show member pathways
12.58 AKT3 BAX CCND1 ERBB2 PTEN
29
Show member pathways
12.56 AKT3 BAX EGFR ERBB2 MDM2 PRKCA
30 12.52 AKT3 CCND1 CDK6 PRKCA TP53
31
Show member pathways
12.51 AKT3 BAX CCND1 MDM2 PTEN TP53
32
Show member pathways
12.48 BAX CCND1 CDK6 MDM2 PTEN TP53
33 12.47 AKT3 BAX CCND1 TP53
34 12.42 CCND1 CDK6 MDM2 TP53
35
Show member pathways
12.42 AKT3 CCND1 EGFR ERBB2 PRKCA
36 12.4 BAX CCND1 CDK6 MDM2 TP53
37
Show member pathways
12.38 AKT3 EGFR ERBB2 PRKCA
38
Show member pathways
12.38 AKT3 BAX CCND1 MDM2 PTEN TP53
39 12.36 BAX H3F3A HIST1H3A MDM2 TP53
40
Show member pathways
12.33 AKT3 BAX CCND1 EGFR ERBB2 MDM2
41
Show member pathways
12.3 AKT3 EGFR PRKCA PTEN
42 12.3 BAX CCND1 EGFR MMP2 TP53
43 12.29 AKT3 CCND1 CDK6 MDM2 PTEN TP53
44 12.27 BAX CCND1 EGFR MDM2 PTEN TP53
45
Show member pathways
12.26 AKT3 EGFR ERBB2 PRKCA PTEN
46
Show member pathways
12.26 AKT3 BAX CCND1 EGFR ERBB2 MDM2
47 12.25 EGFR ERBB2 PRKCA PTEN
48
Show member pathways
12.21 AKT3 CCND1 EGFR MDM2 PTEN
49
Show member pathways
12.17 EGFR H3F3A HIST1H3A PRKCA TP53
50 12.17 BAX EGFR MDM2 MMP2 PTEN TP53

GO Terms for Glioma

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.86 DMBT1 H3F3A HIST1H3A MMP2
2 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.72 BAX MDM2 TP53
3 cellular response to growth factor stimulus GO:0071363 9.71 EGFR ERBB2 MDM2
4 positive regulation of cell cycle GO:0045787 9.67 CCND1 MDM2 TP53
5 ERBB2 signaling pathway GO:0038128 9.65 EGFR ERBB2 PRKCA
6 cellular response to organic substance GO:0071310 9.63 BAX CCND1 MDM2
7 response to steroid hormone GO:0048545 9.61 CCND1 IDH1 MDM2
8 response to magnesium ion GO:0032026 9.58 CCND1 MDM2
9 mitotic G1 DNA damage checkpoint GO:0031571 9.57 CCND1 TP53
10 isocitrate metabolic process GO:0006102 9.51 IDH1 IDH2
11 regulation of cell motility GO:2000145 9.5 CDK6 EGFR ERBB2
12 positive regulation of cell growth GO:0030307 9.46 EGFR ERBB2 H3F3A LGI1
13 cell proliferation GO:0008283 9.43 BAX EGFR ERBB2 LGI1 PTEN TP53
14 response to UV-A GO:0070141 9.4 CCND1 EGFR
15 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
16 glyoxylate cycle GO:0006097 9.26 IDH1 IDH2
17 response to organic cyclic compound GO:0014070 9.02 CCND1 EGFR IDH1 PTEN TP53
18 protein phosphorylation GO:0006468 10 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 BAX EGFR ERBB2 IDH1 MDM2 PTEN
2 kinase activity GO:0016301 9.88 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
3 protein kinase activity GO:0004672 9.8 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
4 protein heterodimerization activity GO:0046982 9.73 BAX EGFR ERBB2 H3F3A HIST1H3A TP53
5 protein phosphatase binding GO:0019903 9.63 EGFR ERBB2 TP53
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.43 EGFR ERBB2
7 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
8 enzyme binding GO:0019899 9.1 CCND1 EGFR MDM2 PRKCA PTEN TP53
9 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2

Sources for Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....